Menu Search
Equities

Novocure Ltd

NVCR:NSQ

Novocure Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)17.82
  • Today's Change-0.37 / -2.03%
  • Shares traded1.01m
  • 1 Year change+60.11%
  • Beta0.7100
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Novocure Ltd's revenues fell -5.30%from 537.84m to 509.34m. In addition, the company has been unable to reduce the cost of goods sold, selling, general and administrative expenses and interest paid (all as a percentage of sales). This has contributed to a 123.75% reduction in net income from a loss of 92.53m to a larger loss of 207.04m.
Gross margin76.42%
Net profit margin-25.93%
Operating margin-27.51%
Return on assets-12.65%
Return on equity-39.70%
Return on investment-20.29%
More ▼

Cash flow in USDView more

In 2023, Novocure Ltd increased its cash reserves by 109.41%, or 126.73m. Cash Flow from Investing totalled 184.15m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 73.34m for operations while cash generated from financing totalled 15.79m.
Cash flow per share-1.29
Price/Cash flow per share--
Book value per share3.34
Tangible book value per share3.34
More ▼

Balance sheet in USDView more

Novocure Ltd has a Debt to Total Capital ratio of 64.46%, a lower figure than the previous year's 144.27%.
Current ratio1.49
Quick ratio1.44
Total debt/total equity1.81
Total debt/total capital0.6446
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.